Expression and clinical significance of DcR3 in cervical cancer

Journal of Xi'an Jiaotong University (Medical Sciences)

Volumn 34, Issue 2, 2013, Pages 224-228

  Wang, Zhi Rong ^a   Xing, Lan Ying ^a   Liu, Ning Xia ^a   Wang, Xiao Xiao ^a   Feng, Min Juan ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cervical cancer; Decoy receptor 3 (DcR3); Enzyme linked immunosorbent assay (ELISA); Immu nocytochemistry

Indexed keywords

DEATH DECOY RECEPTOR 3; DECOY RECEPTOR 3; PEROXIDASE; STREPTAVIDIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 84875297106     PISSN: 16718259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. PARKIN D M. The global health burden of infection-associated cancers in the year 2002[J]. Int J Cancer, 2006, 118(12): 3030-3044.
2. TSUJI S, HOSOTANI R, YONEHARA S, et al. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma[J]. Int J Cancer, 2003, 106(1): 17-25.
3. ROTH W, ISENMANN S, NAKAMURA M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis[J]. Cancer Res, 2001, 61(6): 2759-2765.
4. PITTI R M, MARSTERS S A, LAWRENCE D A, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer[J]. Nature, 1998, 396(6712): 699-703.
5. YU K Y, KWON B, NI J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses light-mediated apoptosis[J]. J Biol Chem, 1999, 274(20): 13733-13736.
6. MARTIN T R, HAGIMOTO N, NAKAMURA M, et al. Apoptosis and epithelial injury in the lungs[J]. Proc Am Thorac Soc, 2005, 2(3): 214-220.
7. YANG C R, HSIEH S L, TENG C M, et al. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1a, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action[J]. Cancer Res, 2004, 64(3): 1122-1129.
8. YANG M, CHEN G, DANG Y, et al. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients[J]. Upsala J Med Sci, 2010, 115(4): 232-237.
9. BAI C, CONNOLLY B, METZKER M L, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster[J]. Proc Natl Acad Sci USA, 2000, 97(3): 1230-1235.
10. GE Z, SANDERS A J, YE L, et al. Expression of death decoy receptor-3(DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro[J]. J Exp Ther Oncol, 2011, 9(2): 109-118.
11. MACHER-GOEPPINGER S, AULMANN S, WAGENER N, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer[J]. Neoplasia, 2008, 10: 1049-1056.
12. ROTH W, ISENMANN S, NAKAMURA M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis[J]. Cancer Res, 2001, 61(6): 2759-2765.
13. OHSHIMA K, HARAOKA S, SUGIHARA M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas[J]. Cancer Lett, 2000, 160(1): 89-97.
14. 2009, 15(11): 988-989.
15. SHEN H W, GAO S L, WU Y L, et al. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis[J]. World J Gastroenterol, 2005, 11(38): 5926-5930.